Cargando…

Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent

OBJECTIVES: To analyse the effect of biological agents (BAs) in terms of achieving inactive disease (ID) or clinical remission (CR) in patients with systemic juvenile idiopathic arthritis (SJIA), to describe effects of switching or discontinuing a BA and to assess the proportion of patients able to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Woerner, A, Uettwiller, F, Melki, I, Mouy, R, Wouters, C, Bader-Meunier, B, Quartier, P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2015
Materias:	Paediatric Rheumatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4613174/ https://www.ncbi.nlm.nih.gov/pubmed/26509061 http://dx.doi.org/10.1136/rmdopen-2014-000036

Ejemplares similares

PReS-FINAL-2133: Drug survival and switching of biological agents in systemic juvenile idiopathic arthritis
por: Woerner, A, et al.
Publicado: (2013)

Chronic and recurrent non-infectious paediatric-onset uveitis: a French cohort
por: Morelle, Guillaume, et al.
Publicado: (2019)

Juvenile idiopathic arthritis and risk of cancer before and after the introduction of biological therapies
por: Horne, AnnaCarin, et al.
Publicado: (2019)

Drivers of non-zero physician global scores during periods of inactive disease in juvenile idiopathic arthritis
por: Alongi, Alessandra, et al.
Publicado: (2022)

Immunome perturbation is present in patients with juvenile idiopathic arthritis who are in remission and will relapse upon anti-TNFα withdrawal
por: Leong, Jing Yao, et al.
Publicado: (2019)

Methotrexate therapy associated with a reduced rate of new-onset uveitis in patients with biological-naïve juvenile idiopathic arthritis
por: van Straalen, Joeri W, et al.
Publicado: (2023)

Juvenile idiopathic arthritis in adulthood: fulfilment of classification criteria for adult rheumatic diseases, long-term outcomes and predictors of inactive disease, functional status and damage
por: Oliveira-Ramos, Filipa, et al.
Publicado: (2016)

The majority of newly diagnosed patients with juvenile idiopathic arthritis reach an inactive disease state within the first year of specialised care: data from a German inception cohort
por: Sengler, Claudia, et al.
Publicado: (2015)

Patterns of clinical joint inflammation in juvenile idiopathic arthritis
por: Heckert, Sascha L, et al.
Publicado: (2023)

Timing matters: real-world effectiveness of early combination of biologic and conventional synthetic disease-modifying antirheumatic drugs for treating newly diagnosed polyarticular course juvenile idiopathic arthritis
por: Huang, Bin, et al.
Publicado: (2020)

Genomic risk scores for juvenile idiopathic arthritis and its subtypes
por: Cánovas, Rodrigo, et al.
Publicado: (2020)

ADA2 deficiency: case report of a new phenotype and novel mutation in two sisters
por: Uettwiller, F, et al.
Publicado: (2016)

Clinical features of children with enthesitis-related juvenile idiopathic arthritis / juvenile spondyloarthritis followed in a French tertiary care pediatric rheumatology centre
por: Goirand, Maxime, et al.
Publicado: (2018)

Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
por: Ravelli, Angelo, et al.
Publicado: (2016)

Validating 10-joint juvenile arthritis disease activity score cut-offs for disease activity levels in non-systemic juvenile idiopathic arthritis
por: Backström, Maria, et al.
Publicado: (2019)

PReS-FINAL-2111: Cytomegalovirus, Epstein Barr virus and Varicella-Zoster virus infections in children with juvenile idiopathic arthritis treated with biologics
por: Remy Piccolo, V, et al.
Publicado: (2013)

Prevalence of autoimmune diseases and other associated conditions in children and young adults with juvenile idiopathic arthritis
por: Lovell, Daniel J, et al.
Publicado: (2021)

Medication burden in young adults with juvenile idiopathic arthritis: data from a multicentre observational study
por: Montag, Laura J, et al.
Publicado: (2022)

Health-related quality of life and disability in adults with juvenile idiopathic arthritis: comparison with adult-onset rheumatic diseases
por: Oliveira Ramos, Filipa, et al.
Publicado: (2021)

Antibiotic exposure in prenatal and early life and risk of juvenile idiopathic arthritis: a nationwide register-based cohort study
por: Hestetun, Sigrid, et al.
Publicado: (2023)

Development and reliability of a novel ultrasonographic joint-specific scoring system for synovitis with reference atlas for patients with juvenile idiopathic arthritis
por: Sande, Nina Krafft, et al.
Publicado: (2021)

Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis: results from the PREVENT-JIA trial
por: Gerss, Joachim, et al.
Publicado: (2022)

Complications of complications: diagnosis and treatment of recurrent macrophage activation syndrome in a patient with well-controlled systemic juvenile idiopathic arthritis
por: Macaraeg, Marci, et al.
Publicado: (2023)

Long‐Term Outcomes Following Achievement of Clinically Inactive Disease in Juvenile Idiopathic Arthritis: The Importance of Definition
por: Shoop‐Worrall, Stephanie J. W., et al.
Publicado: (2018)

Combined genetic analysis of juvenile idiopathic arthritis clinical subtypes identifies novel risk loci, target genes and key regulatory mechanisms
por: López-Isac, Elena, et al.
Publicado: (2021)

Serum calprotectin (S100A8/A9): a promising biomarker in diagnosis and follow-up in different subgroups of juvenile idiopathic arthritis
por: La, Céline, et al.
Publicado: (2021)

Associations between power Doppler ultrasound findings and B-mode synovitis and clinical arthritis in juvenile idiopathic arthritis using a standardised scanning approach and scoring system
por: Sande, Nina Krafft, et al.
Publicado: (2023)

Children with extended oligoarticular and polyarticular juvenile idiopathic arthritis have alterations in B and T follicular cell subsets in peripheral blood and a cytokine profile sustaining B cell activation
por: Tomé, Catarina, et al.
Publicado: (2023)

Impact of biologics on growth in children with juvenile idiopathic arthritis
por: Uettwiller, F, et al.
Publicado: (2011)

Malignancy incidence in 5294 patients with juvenile arthritis
por: Zahedi Niaki, Omid, et al.
Publicado: (2016)

The Biologic Basis of Clinical Heterogeneity in Juvenile Idiopathic Arthritis
por: Eng, Simon W M, et al.
Publicado: (2014)

Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open‐Label, Randomized Study
por: Quartier, Pierre, et al.
Publicado: (2020)

Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial
por: Brunner, Hermine I, et al.
Publicado: (2023)

Juvenile Idiopathic Arthritis in the Era of International Cooperation
por: Uziel, Yosef
Publicado: (2017)

The French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
por: Quartier, Pierre, et al.
Publicado: (2018)

Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate
por: Lovell, Daniel J, et al.
Publicado: (2020)

Refractory systemic onset juvenile idiopathic arthritis: current challenges and future perspectives
por: Ambler, William G., et al.
Publicado: (2022)

Sustained remission after haploidentical bone marrow transplantation in a child with refractory systemic juvenile idiopathic arthritis
por: Morelle, Guillaume, et al.
Publicado: (2021)

Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes
por: Urien, Saik, et al.
Publicado: (2013)

Tocilizumab in the treatment of mixed connective tissue disease and overlap syndrome in children
por: Cabrera, Natalia, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_85kb2efojcgl6b7adfdmt58t6u